Psychiatric News (10/30) reports a study found that adults with serious mental illness (SMI) are more likely to develop long COVID, or “post-acute sequelae of SARS-CoV-2 infection (PASC).” The researchers “used health records data from the National Patient-Centered Clinical Research Network to compare outcomes over six months for 1.6 million U.S. adults with a confirmed COVID-19 infection between March 2020 and October 2022 who also attended a follow-up visit 30 or more days postinfection.” They observed that “among patients with a prior SMI, 28% developed PASC. After adjusting for demographics, people with any SMI were 10% more likely to develop PASC. The increased risk held true for each individual SMI category; COVID patients with schizophrenia, bipolar disorder, or recurrent depression were 7%, 14%, and 8% more likely to develop PASC, respectively.” The study was published in JAMA Network Open.

Related Links:

— “Adults with Serious Mental Illness Face Increased Risk of Long COVID, Psychiatric News, October 30, 2025

The Los Angeles Times (10/30, Purtill) reports that clinics have advertised “something called magnetic e-resonance therapy, or MERT, as a therapy for autism.” The clinics “licensing MERT have claimed that their trademarked version of the treatment can also produce ‘miraculous results’ in kids with autism, improving their sleep, emotional regulation and communication abilities. A six-week course of MERT sessions typically costs $10,000 or more.” However, the FDA “hasn’t approved MERT for this use.” Although off-label prescribing “is a legal and common practice in medicine,” a group of researchers “argue in a new peer-reviewed editorial in the medical journal Transcranial Magnetic Stimulation” that when “such treatments are offered to vulnerable people,” they should be “evidence-based, clearly explained to patients and priced in a way that reflects the likelihood that they will work as advertised. Most clinics advertising off-label TMS as a therapy for autism don’t meet those standards, the researchers say.” The editorial singles out MERT as an “example of off-label TMS where there is negligible evidence of efficacy.”

Related Links:

— “Families pay thousands for an unproven autism treatment. Researchers say we need ethical guidelines for marketing the tech,”Corinne Purtill, Los Angeles Times, October 30, 2025

NPR (10/29, Chatterjee) reports a study found that “teens who start using cannabis before age 15 are more likely to use the drug often later in their lives.” Study results indicate that “they are also more likely to develop mental and physical health problems in young adulthood compared to their peers who did not use the drug in adolescence.” Researchers found that “early, frequent cannabis users had a 51% higher chance of seeking care for mental health problems in young adulthood compared to those who didn’t use the drug.” The findings were published in JAMA Network Open.

Related Links:

— “Teens who use weed before age 15 have more trouble later, a study finds,”Rhitu Chatterjee, NPR, October 29, 2025

The New York Times (10/29, Abelson, Sanger-Katz) reports the administration “has released a preview of the available plans sold through” ACA “marketplaces in 30 states, giving Americans who buy their own health insurance a first look at just how much prices would go up.” Insurers have significantly increased rates “for next year – an average of about 30% for a typical plan in the 30 states where the federal government manages markets, and an average of 17% in states that run their own markets, according to a new analysis from KFF.” However, “the biggest impact for nearly all Americans covered by” ACA “plans will occur with the expiration of generous subsidies at the end of the year unless Congress extends them.” Prices on healthcare.gov “reflect that change using calculations based on a return to the lower subsidy levels offered before 2021.”

Related Links:

— The New York Times (requires login and subscription)

Healio (10/28, Monostra) reports researchers wrote in a study that “GLP-1s hold promise as a potential treatment for alcohol and substance use disorders.” The researchers “discussed how GLP-1s are tied to several changes in the central nervous system and suggested the activation of GLP-1 receptors could reduce ‘drug-seeking and consummatory behaviors.’” They wrote “that some studies have found certain forms of obesity have phenotype characteristics that resemble addiction. Additionally, some therapies used to treat alcohol or substance use disorders, such as naltrexone and topiramate, are also used for obesity.” They called for “more research, including more studies to assess the mechanisms of GLP-1s as they relate to substance use disorders and more randomized controlled trials to evaluate efficacy and safety.” The studywas published in the Journal of the Endocrine Society.

Related Links:

— “GLP-1s may offer ‘real impact’ for treating alcohol and substance use disorders,”Michael Monostra, Healio, October 28, 2025